

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 19597

Title: Gastric cancer: The times they are a changin'

Reviewer's code: 03016888

Reviewer's country: Japan

Science editor: Jing Yu

Date sent for review: 2015-05-15 13:01

Date reviewed: 2015-06-15 20:21

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The authors reported a review article about the treatment of gastric cancer, and well-reviewed comprehensively, from surgery, cytotoxic agents to immunotherapy. In the ASCO 2015, however, the newest results of clinical trials are reported. Some points about clinical trials would be better to revise updated data. 1. In the CYTOTOXIC CHEMOTHERAPY section, the authors mentioned RAINBOW trials in the last paragraph. They mentioned this study using docetaxel, however, not docetaxel but paclitaxel. The authors should revise this sentence. 2. In ANGIOGENESIS INHIBITORS section, the authors mentioned apatinib which is selective VEGFR-2 tyrosine kinase inhibitor. In ASCO 2014, the results of phase 3 trial comparing BSC with apatinib were already reported. The newest data is better. 3. In HGF-c-MET AXIS section, the authors mentioned RILOMET-1 study and MetMAb. These two phase 3 studies were already reported in ASCO 2015. These were negative studies. The newest data is better. 4. In IMMUNOTHERAPY section, the results of KEYNOTE-012 study is mentioned. In ASCO 2015, the updated data of median OS was reported (11.4 mo). Could the authors revise the data? 5. By searching "Clinicaltrials.gov", two on-going phase 3 studies are hit. One is KEYNOTE-061 trial (NCT02370498) which compares pembrolizumab with paclitaxel as second-line setting. Another one



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

is nivolumab vs. BSC as the last-line (NCT02267343). 6. There are many misused characters.